Bovi-Shield Gold 4 Cattle Vaccine

By Zoetis Animal Health

 

For vaccination of healthy cattle to prevent respiratory disease caused by IBR virus and viremia caused by BVD virus Types 1 and 2; and as an aid in preventing respiratory disease caused by BVD virus Types 1 and 2 and PI3 virus.  A duration of immunity of at least 9 months has been demonstrated against IBR and BVD virus Types 1 and 2 disease.  When administered intramuscularly, Bovi-Shield GOLD 4 aids in preventing respiratory disease caused by IBR and BVD virus Types 1 and 2.  Bovi-shield Gold 4 may be administered to pregnant cattle provided they were vaccinated, according to label directions, with any Bovi-Shield Gold FP® or PregGuard® GOLD FP vaccine within the past 12 months.  Bovi-Shield 4 may also be administered to calves nursing pregnant cows provided their dams were vaccinated within the past 12 months as described above.  To help ensure safety in pregnant cattle, heifers must receive at least 2 doses of any Bovi-Shield GOLD FP or PregGuard GOLD FP product with the second dose administered approximately 30 days prebreeding.

 

Directions:  Aseptically rehydrate the freeze-dried vaccine with the sterile diluent provided, shake well, and administer 2 ml subcutaneously or intramuscularly.

 

Precautions:  Do not use in pregnant cows (abortions can result) unless they were vaccinated, according to label directions, with any Bovi-Shield GOLD FP or PregGuard GOLD FP vaccine within the past 12 months.  Do not use in calves nursing pregnant cows unless their dams were vaccinated within the past 12 months as described above.

 

Store at 2°-7°C.  Do not freeze.  Use entire contents when first opened.  Sterilized syringes and needles should be used to administer this vaccine.  Do not sterilize with chemicals because traces of disinfectant may inactivate the vaccine.  Burn containers and all unused contents.  Do not vaccinate within 21 days of slaughter.  Contains gentamicin as preservative.  In case of anaphylaxis, administer epinephrine or equivalent.

 



Our Terms of Use and Privacy Policy have changed. By continuing to browse this site, you agree to the Terms of Use and Privacy Policy.